SCOLR’s Extended-Relase Ibuprofen Plans Ramp Up After Break With Wyeth
This article was originally published in The Pink Sheet Daily
Executive Summary
SCOLR Pharma plans to file NDA for extended-release ibuprofen in latter half of 2008.
You may also be interested in...
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers
Sure Nature Can “Kiss” ImmunaSure Ad Goodbye – NAD
Sure Nature claims its ImmunaSure dietary supplement can help "kiss your cold sores goodbye," but the National Advertising Division does not embrace the pitch